Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 5Observational 1Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Adenocarcinoma 1

Interventions

Blood Specimen Collection 6Radiotherapy 2Quality of Life 2Phlebotomy 2Interviews as Topic 2Drug Therapy 2zolbetuximab 1trastuzumab deruxtecan 1sargramostim 1pembrolizumab 1iopromide 1capecitabine-irinotecan combination 1X-Rays 1Tumor Burden 1Transurethral Resection of Prostate 1Tomography, X-Ray Computed 1Therapeutics 1Surveys and Questionnaires 1Risedronic Acid 1Registries 1Raloxifene Hydrochloride 1Radiofrequency Ablation 1Radiation, Ionizing 1Radiation 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Induction Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Adenocarcinoma × zolbetuximab × Clear all
NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Astellas Pharma Inc

Recruiting
377 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡